NASDAQ: PRPOPrecipio Inc Stock
$0.30-0.02 (-6.25%)
Updated Sep 20, 2023
PRPO Price
$0.30
Fair Value Price
$0.40
Market Cap
$8.16M
52 Week Low
$0.28
52 Week High
$1.02
P/E
-0.64x
P/B
0.58x
P/S
0.87x
PEG
N/A
Dividend Yield
N/A
Revenue
$10.96M
Earnings
-$10.79M
Gross Margin
28.8%
Operating Margin
-98.35%
Profit Margin
-98.5%
Debt to Equity
0.38
Operating Cash Flow
-$7M
Beta
0.78
Next Earnings
Nov 13, 2023
Ex-Dividend
N/A
Next Dividend
N/A
PRPO Overview
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PRPO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PRPO ($0.30) is undervalued by 26.67% relative to our estimate of its Fair Value price of $0.40 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PRPO ($0.30) is significantly undervalued by 26.67% relative to our estimate of its Fair Value price of $0.40 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
PRPO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PRPO due diligence checks available for Premium users.
Be the first to know about important PRPO news, forecast changes, insider trades & much more!
PRPO News
Valuation
PRPO fair value
Fair Value of PRPO stock based on Discounted Cash Flow (DCF)
Price
$0.30
Fair Value
$0.40
Undervalued by
25.68%
PRPO ($0.30) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PRPO ($0.30) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PRPO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PRPO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.64x
Industry
26.23x
Market
14.54x
PRPO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.58x
Industry
4.01x
PRPO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PRPO's financial health
Profit margin
Revenue
$3.5M
Net Income
-$2.3M
Profit Margin
-64.9%
PRPO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PRPO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$19.5M
Liabilities
$5.4M
Debt to equity
0.38
PRPO's short-term liabilities ($4.72M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PRPO's short-term assets ($4.35M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PRPO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PRPO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.2M
Investing
-$32.0k
Financing
$1.7M
PRPO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PRPO vs Diagnostic & Research Stocks
Precipio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.